Today, Daiwa Securities Group Inc. Buys 2,000 Shares of Edwards Lifesciences Corp (EW)

Today, Daiwa Securities Group Inc. Buys 2,000 Shares of Edwards Lifesciences Corp (EW)
Daiwa Securities Group Inc. boosted its position in Edwards Lifesciences Corp (NYSE:EW) by 4.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 42,750 shares of the medical research company’s stock after buying an additional 2,000 shares during the period. Daiwa Securities Group Inc.’s holdings in Edwards Lifesciences Corp were worth $5,154,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in Edwards Lifesciences Corp during the second quarter valued at about $100,000. Spirit of America Management Corp NY bought a new stake in Edwards Lifesciences Corp during the third quarter valued at about $121,000. TCI Wealth Advisors Inc. boosted its stake in Edwards Lifesciences Corp by 30.5% in the third quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company’s stock valued at $126,000 after buying an additional 244 shares in the last quarter. Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corp by 28.9% in the third quarter. Cornerstone Advisors Inc. now owns 1,075 shares of the medical research company’s stock valued at $130,000 after buying an additional 241 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences Corp by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock valued at $106,000 after buying an additional 25 shares in the last quarter. 83.99% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Corp (NYSE:EW) traded down 1.25% during trading on Friday, reaching $85.77. The company had a trading volume of 1,838,400 shares. The company has a 50 day moving average price of $102.00 and a 200 day moving average price of $106.84. The company has a market capitalization of $18.34 billion, a PE ratio of 33.90 and a beta of 0.71. Edwards Lifesciences Corp has a 52-week low of $72.20 and a 52-week high of $121.75.

Edwards Lifesciences Corp (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.68. The firm earned $739.40 million during the quarter, compared to analyst estimates of $749.14 million. Edwards Lifesciences Corp had a return on equity of 24.32% and a net margin of 19.24%. The company’s revenue was up 20.1% on a year-over-year basis. During the same period last year, the company earned $0.54 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Corp will post $2.88 EPS for the current fiscal year.

EW has been the subject of several recent research reports. JPMorgan Chase & Co. reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corp in a research note on Thursday, July 28th. Zacks Investment Research lowered shares of Edwards Lifesciences Corp from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. JMP Securities boosted their target price on shares of Edwards Lifesciences Corp from $125.00 to $130.00 and gave the company a “market outperform” rating in a research note on Thursday, July 28th. Canaccord Genuity reiterated a “buy” rating and set a $140.00 target price on shares of Edwards Lifesciences Corp in a research note on Thursday, August 18th. Finally, Credit Suisse Group AG set a $116.00 target price on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a research note on Thursday, August 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $117.68.

In other Edwards Lifesciences Corp news, VP Huimin Wang sold 13,650 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $120.04, for a total transaction of $1,638,546.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Larry L. Wood sold 13,257 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $119.27, for a total value of $1,581,162.39. The disclosure for this sale can be found here. 2.37% of the stock is owned by corporate insiders.

Edwards Lifesciences Corp Company Profile

Related posts

Leave a Comment